Asuragen, Inc. To Provide GLP Laboratory Testing Services to Aid a Leading Biotechnology Organizatio

May 29, 05:04 AM

Current Headlines: Asuragen, Inc., an oncology molecular diagnostic company and molecular biology service provider, announced today it was selected to provide GLP compliant laboratory testing to assist in gene expression studies being conducted by Millennium Pharmaceuticals of Cambridge, MA.

Asuragen, a cGMP/GLP facility, is dedicated to helping the scientific community and industry to discover and develop new products for the advancement of cancer research and companion diagnostics.

"We are committed to applying our RNA expertise to produce the data quality required in clinical studies with organizations such as Millennium and believe that research like this may enable companion diagnostics and support the value of personalized medicine," commented Scott Hunicke-Smith, V.P. and General Manager of Asuragen Services.

About Asuragen, Inc.

Asuragen is a fully integrated diagnostic reagent company focused on molecular oncology and early detection of cancer, with emphasis on miRNA. Asuragen is empowered with not only a high level of scientific expertise, but also assay development, business infrastructure, GLP testing services and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products.

For more information, visit www.asuragen.com.